Skip to main content

Lipidated peptide nanostructures for stabilizing hydrogels with sustained skincare bioactivity.

Journal of controlled release : official journal of the Controlled Release Society2025-12-05PubMed
Total: 77.5Innovation: 9Impact: 7Rigor: 7Citation: 8

Summary

A palmitoylated peptide (Pal-KVK) self-assembles into helical ribbon superstructures that stabilize hydrogels and enable sustained release, enhancing skin penetration and peptide stability. Embedding Pal-KVK aggregates in a gelatin matrix yielded a composite hydrogel mask with consumer-validated anti-wrinkle and moisturizing benefits.

Key Findings

  • Pal-KVK self-assembles from lamellae to double-layer lamellae and helical ribbon superstructures forming a stable hydrogel.
  • Self-assembled structures provide sustained release of Pal-KVK with enhanced skin penetration and biocompatibility.
  • Embedding Pal-KVK aggregates in gelatin yields a composite hydrogel mask with prolonged skincare efficacy.
  • Consumer dermatological evaluations demonstrated anti-wrinkle and moisturizing benefits of the Pal-KVK/gelatin hydrogel mask.

Clinical Implications

Suggests a path to longer-lasting topical benefits with fewer applications, supporting development of hydrogel masks/patches that improve adherence and outcomes in cosmetic dermatology.

Why It Matters

This work introduces a structurally programmed peptide reservoir that delivers sustained, biocompatible skincare activity with human consumer corroboration, offering a translatable platform for next-generation topical formulations.

Limitations

  • Lack of randomized, controlled clinical trials and unspecified consumer sample size
  • Long-term safety, stability under real-world conditions, and batch-to-batch reproducibility not fully addressed

Future Directions

Conduct randomized controlled trials versus standard creams/serums, quantify in vivo skin pharmacokinetics, and assess manufacturability and regulatory compliance for cosmetic use.

Study Information

Study Type
Case series
Research Domain
Treatment
Evidence Level
IV - Preclinical experimental study with non-randomized human consumer evaluation
Study Design
OTHER